Teva Pharmaceutical Industries Ltd. Recently announced that the FDA has granted approval for the company’s Abbreviated New Drug Application (ANDA) for Cabergoline Tablets, 0.5 mg. Shipment of the product will begin immediately.
Teva’s Cabergoline Tablets are the AB-rated generic equivalent of Pharmacia & Upjohn’s Dostinex® Tablets, a product indicated for treatment of hyperprolactinemic disorders.
Total annual sales of this product in the U.S., including brand and generic sales, are approximately $74 million, based on IMS sales data.